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his case is difficult. Meningitis in pa-
tients with inner ear malformations is 
associated with bacteria (e.g., S. pneu-
moniae and Haemophilus influenzae) 
that colonize the upper airways. The 
prevalence of oropharyngeal coloniza-
tion with GBS is low (≈5%), explain-
ing the rarity of GBS meningitis (10). 
Unlike for pneumococcal meningitis, 
which can be prevented at least par-
tially  by  vaccination,  no  vaccine  is 
available for GBS.
Our report adds another example to 
the growing spectrum of invasive GBS 
disease  beyond  infancy.  GBS  is  uni-
formly susceptible to penicillin; there-
fore,  treatment  directed  at  common 
causes of bacterial meningitis is also 
appropriate for GBS (1,10). Cochlear 
implant  recipients  with  symptoms  of 
fever, otitis media, or headache should 
be carefully assessed; if meningitis is 
diagnosed, GBS should be considered 
as a possible causative organism.
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Severe Necrotizing  
Pneumonia in  
Children, Houston, 
Texas, USA
To  the  Editor:  Routine  vacci-
nation  of  children  with  the  7-valent 
pneumococcal  conjugate  vaccine 
(PCV-7; Wyeth Pharmaceuticals, Col-
legeville,  PA,  USA),  initiated  in  the 
United States in 2000, was followed 
within  2  years  by  an  extensive  and 
rapid decline in invasive pneumococ-
cal disease (IPD) (1). During the past 
few years, increasing frequency of in-
vasive  disease  including  necrotizing 
pneumonia  caused  by  serotypes  not 
included in the vaccine has been re-
ported (2). We show an expanded pat-
tern of the changing spectrum of the 
disease associated with nonvaccine se-
rotypes through this report of 4 cases 
of necrotizing pneumonia in children, 
caused by Streptococcus pneumoniae 
serotype 19A.
Over a 6-month period ending in 
March 2008, 4 children (median age 
3.6 years, 1 with asthma) (Table) were 
brought to our hospital with signs of 
respiratory distress and a 4- to 7-day 
history of fever and cough. All had 
decreased  breath  sounds  or  crack-
les,  and  radiologic  studies  showed 
evidence of complicated pneumonia, 
which  led  to  hospital  admission  (3 
to an intensive care unit [ICU]). S. 
pneumoniae  19A  was  isolated  from 
normally sterile sites with each child. 
All  received  intravenous  antimicro-
bial drugs followed by an oral anti-
microbial drug regimen and were dis-
charged in good health. By reviewing 
immunization records, we confirmed 
that all had completed the PCV-7 se-
ries before becoming ill. 
During the same period, compli-
cated pneumonia was identified in 7 
other  inpatients  by  using  the  Inter-
national  Classification  of  Diseases, 
9th  revision,  codes  for  necrotizing 
pneumonia  and  empyema  and  Cur-
rent  Procedural  Terminology  codes 
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for  thoracoscopic  surgery  (median 
age 4.3 years); 2 had asthma, 1 had 
congenital diaphragmatic hernia with 
resultant  left  lung  hypoplasia.  No 
causative organism was identified for 
any of these cases.
As illustrated by our 4 cases, sero-
type 19A is emerging as an increasing 
cause of severe disease such as com-
plicated pneumonia. Although the inci-
dence of IPD in general has decreased 
since the introduction of PCV-7, the 
emergence of nonvaccine serotypes as 
a cause of severe disease is becoming 
more prevalent. Among 8 geographic 
areas  in  the  United  States,  the  inci-
dence of IPD caused by nonvaccine 
serotypes in children <5 years of age 
increased  from  16.3  cases/100,000 
population to 19.9 cases/100,000 pop-
ulation, respectively, from prevaccine 
years 1998–1999 to 2004 (3).
Because organisms were not iso-
lated from the 7 other patients with ne-
crotizing pneumonia during the same 
period,  we  are  unable  to  comment 
on whether S. pneumoniae 19A was 
the predominant cause of necrotizing 
pneumonia  in  our  study.  However, 
in comparing our patients with these 
7 patients, those with S. pneumoniae 
19A appear to have had a more com-
plicated course of illness, longer hos-
pital stays (mean 19 days vs. 13 days), 
and  a  longer  course  of  intravenous 
antimicrobial drugs (mean 19.2 days 
vs. 17 days). Although these 7 patients 
required more video-assisted thoraco-
scopic surgery than did our 4 patients 
(100% vs. 75%), those with S. pneu-
moniae  19A  necrotizing  pneumonia 
had a more severe clinical course of 
illness resulting in more ICU admis-
sions (75% vs. 29%) and intubations 
(75% vs. 14%).
All 4 of our patients had complet-
ed the PCV-7 series before becoming 
ill. The emergence of nonvaccine se-
rotypes as a cause of severe disease 
may be caused by serotype replace-
ment  and  increased  nasopharyngeal 
carriage of nonvaccine serotypes after 
receiving PCV-7 (4). Our report sup-
ports the theory of serotype replace-
ment. The increasing incidence of in-
vasive disease caused by nonvaccine 
serotypes has prompted development 
of  an  expanded  pneumococcal  vac-
cine to include serotypes 1, 3, 5, 6A, 
7F, and 19A in addition to those cov-
ered by PCV-7 (5). The need for this 
expanded vaccine is becoming more 
evident  as  the  number  of  children 
with  severe  pneumococcal  disease 
due to current nonvaccine serotypes 
increases.
Anupama S. Kalaskar,  
Gloria P. Heresi,  
Audrey Wanger,  
James R. Murphy,  
and Susan H. Wootton
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Table. Characteristics of patients in study of severe necrotizing pneumonia in children, Houston, Texas, USA, 2007–2008* 
Patient
Characteristic 1 2 3 4
Age, y  4.1 2.8 3.4 3.7
Race Black White Black Black
Sex  M M F F
Completed PCV-7 series  Yes  Yes  Yes  Yes 
Co-illnesses Asthma None None None
Clinical signs 
  Date  2007 Nov  2007 Nov  2007 Dec  2008 Feb 
  Temperature, °C  37.6 38.9 37.9 38.7
  Pulse, beats/min  154 160 162 188
  Respiratory rate, breaths/min  70 60 40 42
  Blood pressure, mm Hg  95/53 122/84 110/78 106/69
  Oxygen saturation on room air, %  85 90 100 86
Symptoms/signs (hospital) Fever, cough, dyspnea, 
headache, abdominal 
pain, decreased activity 
Fever, cough, dyspnea, 
congestion
Fever, cough  Fever, cough, 
decreased
appetite
Hospital course 
  Site pathogen isolated  Blood and pleural fluid  Blood and pleural fluid  Pleural fluid  Blood
  IV antimicrobial drugs, d   21 9 14 33
  IV antimicrobial drugs (MIC, Pg/mL)  Cefotaxime (0.06)  Vancomycin (0.75); 
ceftriaxone (0.19) 
Vancomycin (1); 
resistant to 
cephalosporin
Vancomycin 
(0.50); ceftriaxone 
(0.064)
  VATS† (duration, d)  Yes (2)  Yes (2)  Yes (2)  No
  ICU stay  Yes  Yes  No  Yes 
  Intubated (duration, d)  Yes (5)  Yes (5)  No Yes (22) 
  Duration of hospitalization, d  22 11 15 28
Oral antimicrobial drugs after discharge 
(duration, d) 
Cefdinir (7)  Cefdinir (14)  Linezolid (14)  Cefdinir (7) 
*PCV, pneumococcal conjugate vaccine; IV, intravenous; VATS, video-assisted thoracoscopic surgery; ICU, intensive care unit. Boldface indicates 
clinically significant differences. 
†Hospitalization day that VATS was performed.  LETTERS
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Human Bocavirus 2 
in Children,  
South Korea
To the Editor: In 2009, Kapoor 
et al. and Arthur et al. published re-
ports on the prevalence of the newly 
identified  parvovirus,  human  bo-
cavirus 2 (HBoV-2), in fecal samples 
(1,2).  HBoV-1  had  been  discovered 
in 2005 (3), and reports indicate its 
possible  role  in  respiratory  diseases 
such as upper respiratory tract infec-
tions,  lower  respiratory  tract  infec-
tions  (LRTIs),  and  in  exacerbation 
of asthma (4); in these diseases, the 
virus co-infects with other respiratory 
viruses  (5).  Systemic  infection  with 
HBoV-1 and possible association of 
this virus with other diseases such as 
gastroenteritis, Kawasaki disease, and 
hepatitis  have  been  reported  (6–8). 
We  looked  for  HBoV-2  in  clinical 
samples  from  children  with  various 
diseases, including acute LRTIs, Ka-
wasaki  disease,  Henoch-Schönlein 
purpura, and hepatitis.
During September 2008–January 
2009, a total of 212 nasopharyngeal 
aspirates  were  collected  from  212 
children (median age 8 months, range 
1–59 months) hospitalized with acute 
LRTIs  at  Sanggyepaik  Hospital  in 
Seoul, South Korea. Previously, dur-
ing January 2002–June 2006, a total of 
173 serum samples had been obtained 
from children (age range 1 month–15 
years) with hepatitis (hepatitis B, 20 
samples;  hepatitis  C,  11  samples; 
unknown hepatitis, 31 samples), Ka-
wasaki disease (12 samples), and He-
noch-Schönlein purpura (18 samples) 
and from healthy children (same age 
range, 81 samples) (9). The study was 
approved by the internal review board 
of Sanggyepaik Hospital. 
DNA was extracted from serum 
samples,  and  RNA  and  DNA  were 
extracted  from  nasopharyngeal  aspi-
rates by using a QIAamp Viral RNA 
Mini Kit (QIAGEN, Hilden, Germa-
ny) and a QIAamp DNA Blood Mini 
Kit  (QIAGEN  GmbH),  respectively. 
All  nasopharyngeal  aspirates  were 
tested  by  PCR  for  common  respira-
tory viruses such as respiratory syncy-
tial virus, influenza viruses A and B, 
parainfluenza  virus,  and  adenovirus, 
as  described  previously  (10).  PCRs 
to detect HBoV-1 were performed by 
using  primers  for  the  nonstructural 
(NS) 1 and nucleocapsid protein (NP) 
1 genes, as described previously (10). 
Additional  PCRs  for  rhinovirus,  hu-
man metapneumovirus, human coro-
navirus  (hCoV)-NL63,  hCoV-OC43, 
hCoV-229E, hCoV HKU-1, WU poly-
omavirus, and KU polyomavirus were 
performed, as described, for HBoV-2
–positive samples (10).
HBoV-2  was  detected  by  per-
forming first-round PCR with primers 
based on the NS gene, HBoV2-sf1, and 
HBoV2-sr1. Second-round PCR was 
performed by using primers HBoV2-
sf2  and  HBoVsr2,  as  described  pre-
viously (1). The PCR products were 
sequenced by using an ABI 3730 XL 
autoanalyzer  (Applied  Biosystems, 
Foster  City,  CA,  USA).  The  nucle-
otide sequences were aligned by us-
ing BioEdit 7.0 (www.mbio.ncsu.edu/
BioEdit/BioEdit.html)  and  presented 
in a topology tree, prepared by using 
MEGA 4.1 (www.megasoftware.net). 
Of  the  212  samples  tested,  the 
following viruses were detected: hu-
man  respiratory  syncytial  virus  (in 
124 [58.4%] samples), human rhino-
virus (24 [11.3%]), influenza virus A 
(18 [8.4%]), adenovirus (10 [4.7%]), 
and  parainfluenza  virus  (8  [3.7%]). 
HBoV-1 was not detected in the study 
population. HBoV-2 DNA was found 
in 5 (2.3%) of the 212 samples collect-
ed; all positive samples had been ob-
tained in October 2008. The age range 
of the children with HBoV-2–positive 
samples  was  4–34  months  (median 
24 months), and all were male. The 
diagnoses  were  bronchiolitis  for  3 
children and bronchopneumonia for 2. 
The most frequently codetected virus 
was human respiratory syncytial virus, 
found in 4 (80%) of 5 samples. One 
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